Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | NMT1 | P30419 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231509 | 0.89 | DPP4 (0.59) | DPP4MAPK8PDE5APDE4APDE4B | |
| SCHEMBL27581821 | 0.89 | DPP4 (0.47) | DPP4MAPK8PPARGNMT1KMT2A | |
| SCHEMBL5235815 | 0.89 | NMT1 (0.49) | DPP4PPARGPDE5APDE4APDE4B | |
| SCHEMBL5238135 | 0.87 | NMT1 (0.47) | DPP4PPARGNMT1KMT2AGABRA1 | |
| SCHEMBL5234388 | 0.85 | DPP4 (0.58) | DPP4MAPK8 | |
| SCHEMBL5235743 | 0.84 | MAPK8 (0.53) | DPP4MAPK8 | |
| SCHEMBL5238527 | 0.84 | MAPK8 (0.60) | DPP4MAPK8PDE5APDE4APDE4B | |
| SCHEMBL5235307 | 0.83 | NMT1 (0.42) | DPP4PPARGNMT1KMT2AGABRA1 | |
| SCHEMBL5238407 | 0.82 | DPP4 (0.57) | DPP4MAPK8PDE5APDE4APDE4B | |
| SCHEMBL5232425 | 0.82 | DPP4 (0.64) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| CN-1500080-A | Fused heterocyclic compounds | ����ҩƷ��ҵ��ʽ���� | 2004-05-26 | — | — | CN | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885MAPK8 2612/4885PPARG 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.